1. Home
  2. FLGT vs VALN Comparison

FLGT vs VALN Comparison

Compare FLGT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$27.16

Market Cap

697.3M

Sector

Health Care

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$8.69

Market Cap

820.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLGT
VALN
Founded
2011
2012
Country
United States
France
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
697.3M
820.0M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
FLGT
VALN
Price
$27.16
$8.69
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$28.33
$15.75
AVG Volume (30 Days)
272.3K
20.4K
Earning Date
11-07-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$315,549,000.00
$211,089,992.00
Revenue This Year
$16.84
$5.08
Revenue Next Year
$9.74
$12.53
P/E Ratio
N/A
N/A
Revenue Growth
13.61
13.48
52 Week Low
$14.57
$3.62
52 Week High
$31.04
$12.25

Technical Indicators

Market Signals
Indicator
FLGT
VALN
Relative Strength Index (RSI) 47.00 44.05
Support Level $26.69 $8.62
Resistance Level $31.04 $9.10
Average True Range (ATR) 0.77 0.29
MACD -0.46 0.02
Stochastic Oscillator 10.80 12.25

Price Performance

Historical Comparison
FLGT
VALN

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: